08-Jan-2021

Merck announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in ...

more

Global coronavirus pandemic has significantly increased demand

08-Dec-2020

Merck announced the broadening of its manufacturing footprint with a combined € 40 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, USA. These sites supply critical products to customers developing lifesaving therapies, including Covid-19 ...

more

Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

03-Dec-2020

Merck and Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs. “Our platform has ...

more

Merck invests € 10 million in modular technical infrastructure

27-Nov-2020

Merck announced a collaborative partnership with Siemens for the digitalization of production. This partnership is to result in the development of a process control system for the modular production of innovative materials and products for the electronics, pharmaceutical and life science ...

more

In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion

12-Nov-2020

Merck grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion. The increase was primarily due to double-digit percentage organic growth in the Life Science business sector and acquisition-related increases in the ...

more

Once approved, new test will help laboratories increase testing capacity and decrease turnaround time for results

02-Nov-2020

Merck announced a collaboration with Mammoth Biosciences Inc., of South San Francisco, California, USA, for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test. Mammoth’s high-throughput systems will be compatible with both nasal swab and ...

more

Platform combined with virotherapy targets cancerous cells while protecting healthy tissue of key organs

21-Oct-2020

Merck announced that Combined Therapeutics Inc., Cambridge, Massachusetts, USA, has been selected as the North American winner of its 2020 Advance Biotech Grant Program. The biotechnology company was selected for its innovative nucleic acid platform which, combined with virotherapy, has the ...

more

Investment of more than € 140 million creates approximately 55 new jobs

12-Oct-2020

Merck celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany. With the new facility, the company plans to expand manufacturing of Millipore Express® membranes, which are critical components in Millipore Express® filters and help ensure the sterility of ...

more

Two internationally experienced managers to join Executive Board

30-Sep-2020

Stefan Oschmann will hand over the Chair of the Executive Board of Merck to Belén Garijo in 2021. The Board of Partners of E.MerckKG has appointed Garijo as new Chair of the Executive Board and CEO of Merck effective May 1, 2021. She is currently Vice Chair of the Executive Board and Deputy CEO ...

more

From today’s perspective targeted smaller to medium-sized acquisitions after 2022 more likely than major transformative deals

17-Sep-2020

Merck expects to deliver continued profitable growth in the coming years despite a challenging market environment. Today at its virtual Capital Markets Day, the company presented to analysts and investors the progress made in realizing the growth and expansion phase of its strategy for the period ...

more